Pulmatrix(NASDAQ) PULM

Current Price$1.73

Market Cap$6.03M

Since IPO (2015)-100%

5 Year-91%

1 Year-71%

1 Month+8%

Pulmatrix last closing stock price
Metric	Price	Date
Last close	USD 1.65	2026-07-24

Pulmatrix stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-2.37%	USD 1.69	2026-07-17
1 month	+7.84%	USD 1.53	2026-06-24
3 month	+22.22%	USD 1.35	2026-04-24
Year to date	-26.01%	USD 2.23	2025-12-31
1 year	-70.59%	USD 5.61	2025-07-24
3 year	-37.02%	USD 2.62	2023-07-25
5 year	-90.73%	USD 17.80	2021-07-23
Since inception	-99.93%	USD 2,360.00	2015-06-16

Pulmatrix Financials at a Glance

Market Cap

$6.03M

Revenue (TTM)

$0.00

Net Income (TTM)

-$4.53M

EPS (TTM)

-$1.24

P/E Ratio

-1.33

Dividend

$0.00

Beta (Volatility)

0.47 (Low)

Dividend

$0.00

Beta (Volatility)

0.47 (Low)

Price

$1.73

Volume

594

Open

$1.65

Price

$1.73

Volume

594

Open

$1.65

Previous Close

$1.73

Daily Range

$1.65 - $1.73

52-Week Range

$1.16 - $5.80

Estimated Earnings Date

Aug 12, 2026

Dividend

$0.00

Beta (Volatility)

0.47 (Low)

Price

$1.73

Volume

594

Open

$1.65

Previous Close

$1.73

Daily Range

$1.65 - $1.73

52-Week Range

$1.16 - $5.80

Estimated Earnings Date

Aug 12, 2026

PULM News

Pulmatrix (PULM) Q2 Revenue Falls 100%

Motley Fool Markets TeamAug 6, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pulmatrix

Pulmatrix develops inhaled medicines for people with lung diseases. Its products aim to help asthma and chronic lung disease patients breathe easier. The company uses a special powder technology to deliver drugs directly to the lungs.

Products and Services

PUR1900 (Pulmazole): Inhaled anti-fungal for asthma and cystic fibrosis; PUR1900 generated all revenue for the six months ended June 30, 2024.

PUR1800: Inhaled drug for chronic obstructive pulmonary disease (COPD); completed early clinical testing.

PUR3100: Inhaled migraine treatment; development paused, no current revenue.

iSPERSE Technology: Powder system for delivering drugs to the lungs; used in the company’s main pipeline products.

Growth and Expansion

Signed a development and commercialization deal with Cipla Technologies in 2019 for Pulmazole outside the US.

Licensed kinase inhibitor candidates from RespiVert.

Entered into a collaboration and license agreement with Sensory Cloud.

Announced a proposed merger with Cullgen in 2025; if completed, Cullgen will become the main business.

Transferred non-US Pulmazole rights to Cipla in 2024 after winding down clinical trials.

What Makes Pulmatrix Stand Out

Pulmatrix’s iSPERSE technology enables efficient delivery of drugs to the lungs, which may reduce side effects. The company holds a large patent portfolio, supporting its competitive position. Its focus on inhaled treatments addresses needs in both lung and migraine care.

Five Things You Need to Know

Revenue was $0 in Q2 2025

Net loss was $1.55M in Q2 2025

Cash and equivalents were $5.8M as of June 30, 2025.

Total operating expenses were $1.55 million in Q2 2025

PUR1900 generated all revenue in 2024; no active sales in 2025.

Bottom Line

Pulmatrix has shifted from active drug development to seeking a merger and asset sales. Its future depends on the outcome of the Cullgen merger and ability to monetize its technology.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Peter B. Ludlum, MBA

Website

www.pulmatrix.com

Headquarters

Framingham, MA 02421, US

PULM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-102.06%

Return on Capital

-135.67%

Return on Assets

-100.67%

Earnings Yield

-75.19%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.03M

Shares Outstanding

3.65M

Volume

594

Avg. Volume

50.43K

Financials (TTM)

Gross Profit

-$52.00K

Operating Income

-$4.61M

EBITDA

-$4.50M

Operating Cash Flow

-$4.69M

Capital Expenditure

$0.00

Free Cash Flow

-$4.69M

Cash & ST Invst.

$3.32M

Total Debt

$0.00

Pulmatrix Performance Analysis

Pulmatrix annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 6,071,000	17.5%
2023	2023-12-31	USD 7,298,000	20.2%
2024	2024-12-31	USD 7,806,000	7.0%
2025	2025-12-31	USD 0	N/A

Pulmatrix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Pulmatrix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -5.46	-36.7%
2023	2023-12-31	USD -3.87	-29.2%
2024	2024-12-31	USD -2.62	-32.3%
2025	2025-12-31	USD -1.41	-46.0%

Pulmatrix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	14.3%
Q3	2025-09-30	42.9%
Q4	2025-12-31	-4.2%
Q1	2026-03-31	-28.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$6.03M

N/A

Market Cap/Employee

$3.01M

N/A

Employees

N/A

Net Income

-$1.17M

+35.2%

EBITDA

-$1.17M

+34.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$3.32M

-56.9%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.01%

N/A

Return on Invested Capital

-1.28%

N/A

Free Cash Flow

-$1.07M

+41.1%

Operating Cash Flow

-$1.07M

+41.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CTXRCitius Pharmaceuticals, Inc.

CTXRCitius Pharmaceuticals, Inc.$0.52-2.07%

CRISCuris, Inc.

CRISCuris, Inc.$4.89+4.71%

FBLGFibroBiologics, Inc. Common Stock

FBLGFibroBiologics, Inc. Common Stock$0.71-3.20%

HOTHHoth Therapeutics, Inc.

HOTHHoth Therapeutics, Inc.$0.80-4.48%

ASBPAspire Biopharma Holdings, Inc.

ASBPAspire Biopharma Holdings, Inc.$7.26+0.69%

LGVNLongeveron Inc.

LGVNLongeveron Inc.$0.60-1.19%

DAREDare Bioscience, Inc.

DAREDare Bioscience, Inc.$1.28+1.59%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

TAT&T

TAT&T$24.13+0.05%

FFord Motor Company

FFord Motor Company$14.37+0.02%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

Questions About PULM

What is the current price of Pulmatrix?

Pulmatrix is trading at $1.73 per share.

What is the 52-week range for Pulmatrix?

Over the past 52 weeks, Pulmatrix has traded between $1.16 and $5.80.

How much debt does Pulmatrix have?

As of the most recent reporting period, Pulmatrix reported total debt of $0.00.

How much cash does Pulmatrix have on hand?

Pulmatrix reported $4.02M in cash and cash equivalents in its most recent financial results.

What is Pulmatrix’s dividend yield?

Pulmatrix does not currently have a dividend yield.

Pulmatrix(NASDAQ) PULM

Pulmatrix Financials at a Glance

PULM News

Pulmatrix (PULM) Q2 Revenue Falls 100%

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Pulmatrix

Products and Services

Growth and Expansion

What Makes Pulmatrix Stand Out

Five Things You Need to Know

Bottom Line

PULM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Pulmatrix Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PULM

What is the current price of Pulmatrix?

What is the 52-week range for Pulmatrix?

How much debt does Pulmatrix have?

How much cash does Pulmatrix have on hand?

What is Pulmatrix’s dividend yield?

Premium Investing Services